Targeted protein degraders are an emerging class of anticancer therapeutics designed to eliminate disease-driving proteins rather than merely inhibit their catalytic or ligand-binding activity. In hormone-driven malignancies, this strategy is particularly relevant because estrogen receptors, androgen receptors, and associated co-regulatory proteins can sustain tumor growth through transcriptional programs that are adaptive, heterogeneous, and often resistant to conventional endocrine blockade. Proteolysis-targeting chimeras, or PROTACs, and related molecular-glue degraders recruit target proteins to the ubiquitin-proteasome system, resulting in their catalytic, event-driven removal. Clinical development has focused principally on estrogen receptor degradation in advanced estrogen receptor-positive breast cancer and androgen receptor degradation in metastatic castration-resistant prostate cancer. Early clinical studies of agents such as vepdegestrant, imlunestrant, and androgen receptor degraders have demonstrated biological activity in selected patients, including those with resistance-associated receptor alterations. Important challenges include incomplete degradation, pharmacokinetic limitations, acquired resistance, toxicity, biomarker selection, and the need to define optimal sequencing with endocrine therapy, CDK4/6 inhibitors, androgen-receptor pathway inhibitors, chemotherapy, and targeted agents. This review summarizes the epidemiology, biology, clinical presentation, diagnosis, management, evidence base, and future clinical role of targeted degraders in hormone-driven cancer.
Hormone-driven cancers represent a major proportion of global cancer morbidity and mortality. Breast and prostate cancers are the most clinically prominent examples, although endometrial, ovarian, and selected other malignancies may also depend on steroid-hormone signaling. Endocrine therapies have transformed outcomes by depriving tumors of hormonal stimulation or blocking hormone receptors. Nevertheless, primary and acquired resistance remains common, particularly in advanced disease. Resistance may arise through receptor mutation, amplification, altered co-regulator recruitment, activation of bypass signaling, lineage plasticity, or incomplete suppression of the relevant transcriptional network.
Targeted degraders seek to address these limitations through a pharmacologic mechanism that removes the receptor from the cell. A typical PROTAC contains a ligand for the target protein, a linker, and a ligand for an E3 ubiquitin ligase. By bringing the target and E3 ligase into proximity, the molecule promotes polyubiquitination and subsequent proteasomal degradation. Because one degrader molecule can participate in multiple rounds of target elimination, the pharmacologic effect may be catalytic rather than stoichiometric. This mechanism can suppress scaffold, transcriptional, and noncanonical receptor functions that may persist during conventional antagonism.
Breast cancer is among the most frequently diagnosed cancers worldwide, and approximately three quarters of breast tumors express estrogen receptor, with or without progesterone receptor expression. Endocrine therapy is therefore central to adjuvant and metastatic management. Despite substantial improvements in survival, metastatic estrogen receptor-positive disease remains generally incurable, and resistance accumulates over time. Clinically relevant resistance mechanisms include ESR1 mutations, which are enriched after aromatase inhibitor exposure, and alterations in cell-cycle, phosphatidylinositol 3-kinase, AKT, and mechanistic target of rapamycin pathways.
Prostate cancer is also a major global health burden. Androgen deprivation and androgen receptor pathway inhibition are foundational treatments for advanced disease. Most tumors initially respond, but many eventually progress to castration-resistant prostate cancer. In this setting, androgen receptor amplification, ligand-binding-domain mutations, constitutively active splice variants, intratumoral steroidogenesis, and lineage transformation can undermine treatment. The substantial population of patients with metastatic hormone-resistant disease provides a strong rationale for therapies capable of removing rather than simply inhibiting the androgen receptor.
Estrogen and androgen receptors are ligand-activated transcription factors. Following hormone binding, they undergo conformational changes, dimerization, nuclear trafficking, DNA binding, and recruitment of co-activators or co-repressors. The resulting transcriptional programs regulate proliferation, differentiation, metabolism, survival, and tissue-specific identity. Tumor cells can exploit this biology by increasing receptor abundance, changing receptor structure, or rewiring downstream signaling.
Degraders can theoretically overcome several of these adaptations. A properly designed estrogen receptor degrader may remove both wild-type and selected mutant receptors, including alterations that reduce the effectiveness of selective estrogen receptor modulators or degraders. An androgen receptor degrader may decrease full-length receptor protein and potentially influence receptor-dependent signaling more broadly than a ligand-binding antagonist. However, degradation is not automatically equivalent to complete pathway suppression. Some tumors retain growth through glucocorticoid receptor signaling, PI3K-AKT-mTOR activation, neuroendocrine differentiation, or receptor-independent transcriptional programs. The extent, duration, and tissue distribution of degradation are therefore clinically important.
Risk factors for hormone-driven cancers vary by organ and include age, inherited susceptibility, reproductive and hormonal exposure, obesity, alcohol use, metabolic disease, family history, and prior atypical or premalignant lesions. In breast cancer, germline pathogenic variants in BRCA1, BRCA2, PALB2, and other genes may contribute to risk, although receptor phenotype is variable. In prostate cancer, age, African ancestry, family history, inherited DNA-repair defects, and selected germline variants are clinically important.
Factors associated with resistance to endocrine therapy include high tumor burden, visceral metastases, rapid disease progression, poor treatment adherence, ESR1 or androgen receptor alterations, receptor amplification, and activation of parallel oncogenic pathways. Prior exposure to aromatase inhibitors, selective estrogen receptor modulators, androgen synthesis inhibitors, or androgen receptor antagonists can select resistant subclones. These factors should inform molecular testing and therapeutic sequencing rather than being viewed as absolute exclusions from degrader treatment.
Clinical manifestations depend on the primary cancer, disease stage, and metastatic sites. Patients with advanced breast cancer may present with breast or chest-wall recurrence, lymphadenopathy, bone pain, pathologic fracture, dyspnea from pulmonary or pleural involvement, liver dysfunction, or neurologic symptoms. Prostate cancer commonly causes lower urinary tract symptoms, hematuria, bone pain, spinal cord compression, anemia, renal obstruction, or constitutional decline. Some individuals remain asymptomatic despite biochemical or radiographic progression.
Treatment resistance may be suggested by rising tumor markers, new lesions, increasing lesion size, worsening symptoms, or progression despite biochemical suppression of circulating sex hormones. Clinicians should recognize that a stable serum marker does not always exclude clinically meaningful progression, particularly in heterogeneous disease or when visceral metastases develop.
Diagnosis requires histopathologic confirmation and assessment of hormone receptor status using validated immunohistochemistry. In breast cancer, estrogen receptor and progesterone receptor expression, HER2 status, tumor grade, proliferation indices, and the clinical pattern of recurrence guide treatment. In prostate cancer, serum prostate-specific antigen, imaging, histology, castration status, metastatic distribution, and the tempo of progression are integrated into classification.
Molecular testing is increasingly important before selecting targeted degraders. Tumor or circulating DNA may identify ESR1 mutations, PIK3CA alterations, AKT-pathway abnormalities, homologous recombination repair defects, or androgen receptor changes. Testing should be interpreted in context because circulating DNA may not capture all metastatic clones, and the absence of a detected alteration does not prove receptor dependence. Baseline imaging, organ-function testing, medication review, and assessment of performance status are essential. Clinical trials should incorporate pharmacodynamic measures such as receptor occupancy, receptor degradation, circulating tumor DNA dynamics, and serial radiographic response whenever feasible.
Standard management remains disease-specific and should follow established multidisciplinary pathways. In hormone receptor-positive metastatic breast cancer, endocrine therapy is commonly combined with a CDK4/6 inhibitor, with subsequent use of agents directed at PI3K-AKT-mTOR signaling, selective estrogen receptor degradation, or other molecular abnormalities when indicated. In advanced prostate cancer, continuous androgen deprivation is generally maintained, supplemented by androgen receptor pathway inhibitors, androgen synthesis blockade, chemotherapy, radioligand therapy, PARP inhibition for appropriate DNA-repair alterations, or other guideline-supported options.
Targeted degraders are being developed as oral therapies, which may offer convenient administration and sustained systemic exposure. Their potential benefits include activity after prior endocrine therapy, efficacy against selected receptor mutations, and a mechanism that reduces receptor abundance rather than merely competing with endogenous hormone. Early breast cancer studies of oral estrogen receptor degraders, including vepdegestrant and imlunestrant, have reported clinically meaningful responses or disease control in subsets of heavily pretreated patients, particularly in tumors with ESR1 alterations. Several androgen receptor degraders have entered clinical testing for metastatic castration-resistant prostate cancer, although efficacy has been variable and remains under active evaluation.
Combination treatment is a major management consideration. Combining degraders with CDK4/6 inhibitors, PI3K or AKT inhibitors, mTOR inhibitors, immune checkpoint inhibitors, or DNA-damaging agents may suppress complementary resistance pathways. Such combinations can also increase cytopenias, gastrointestinal toxicity, hepatic laboratory abnormalities, fatigue, or metabolic complications. Treatment selection should therefore account for prior therapies, comorbidities, drug interactions, patient preferences, and the availability of validated biomarkers.
Recent progress has involved improved ligand design, selective E3 ligase recruitment, linker optimization, enhanced oral bioavailability, and development of degraders active against mutant receptor conformations. Estrogen receptor degraders are the most clinically mature group. Ongoing trials are evaluating their use after CDK4/6 inhibition, in earlier lines of metastatic disease, and in combination with pathway-directed therapies. The clinical value of these agents may be greatest when selected according to ESR1 mutation status, prior treatment exposure, and evidence of persistent receptor dependence.
Androgen receptor degraders remain an important but technically challenging area. The androgen receptor is a large, multifunctional protein, and resistance may involve splice variants that lack the ligand-binding domain. Degraders directed against domains beyond the conventional ligand-binding site, or compounds capable of reducing both full-length and clinically relevant variants, may broaden activity. Molecular glues and heterobifunctional degraders that recruit alternative E3 ligases are also being investigated. These approaches could improve tissue selectivity, overcome resistance to commonly used E3 ligase systems, and expand the range of degradable cancer proteins.
Current professional guidelines generally recommend using approved endocrine agents, targeted combinations, chemotherapy, and biomarker-directed treatments according to tumor type, stage, prior therapy, and patient fitness. Targeted degraders should be prescribed only within their regulatory indications or well-designed clinical trials unless a specialist multidisciplinary team determines otherwise. Receptor status should be confirmed when clinically appropriate, and molecular testing should be performed when it can change treatment selection.
Clinicians should document baseline disease burden, liver and renal function, concomitant medications, and cardiac or metabolic risk where relevant. Response should be assessed using symptoms, physical examination, laboratory markers, and interval imaging rather than a single measure. Adverse-event monitoring should include fatigue, gastrointestinal effects, cytopenias, hepatic abnormalities, menopausal or androgen-deprivation symptoms, and potential class-specific effects. Patients should be informed that investigational degraders may provide meaningful benefit but that long-term survival data, optimal sequencing, and rare toxicities may remain uncertain.
The central clinical promise of targeted degradation is the possibility of converting receptor biology from a persistent signaling dependency into a therapeutically removable vulnerability. This may be particularly useful in tumors with receptor overexpression, activating receptor mutations, or incomplete response to competitive antagonists. Oral administration and a mechanism compatible with combination treatment may further support integration into outpatient oncology practice.
Important risks include on-target endocrine effects, off-target protein degradation, pharmacokinetic interactions, hepatotoxicity, fatigue, gastrointestinal symptoms, cytopenias, and additive toxicity during combination therapy. Resistance may emerge through loss or alteration of the target protein, impaired ubiquitin-proteasome function, changes in E3 ligase expression, inadequate intracellular drug concentration, or activation of bypass pathways. Clinical outcomes should therefore be interpreted alongside pharmacodynamic evidence and molecular evolution, not solely through initial tumor shrinkage.
Expert development priorities include identifying the patients most likely to remain receptor-dependent, establishing standardized assays for target degradation, and defining clinically meaningful thresholds for pharmacodynamic activity. Serial circulating tumor DNA, paired biopsies, functional imaging, and computational analysis of clonal evolution may help distinguish pharmacologic failure from biological escape. Adaptive clinical trials could evaluate treatment switching based on emerging receptor alterations rather than waiting for extensive radiographic progression.
Future research will likely emphasize tissue-selective degradation, brain-penetrant compounds, degraders for receptor variants, and rational combinations that prevent bypass signaling. Earlier use in adjuvant or neoadjuvant settings is attractive but requires rigorous evidence because tolerability and long-term safety standards are higher in patients with potentially curable disease. The field will also need transparent comparative trials against established endocrine agents, health-economic analyses, and real-world studies addressing adherence and equitable access.
Targeted degraders represent a mechanistically distinctive advance in the treatment of hormone-driven cancer. By recruiting endocrine receptor proteins to the ubiquitin-proteasome system, these agents may overcome selected forms of resistance that limit conventional receptor blockade. Estrogen receptor degraders have generated the strongest clinical evidence to date, while androgen receptor degraders and next-generation molecular glues remain active areas of investigation. Their eventual role will depend on validated biomarkers, durable clinical benefit, reliable pharmacodynamic assays, manageable toxicity, and evidence-based sequencing with existing therapies. At present, targeted degraders should be integrated through approved indications and clinical trials, with treatment decisions guided by tumor biology, prior exposure, patient comorbidity, and multidisciplinary expertise.
1.
Big Comeback for Myeloma Drug; DIY Cancer Therapy; Gut Clues to Bladder Cancer
2.
Pressing the Sleep button could have a positive impact on cognition.
3.
Simpler Screening Criteria Could Catch More Lung Cancers
4.
An understudied type of breast cancer poses a lurking threat
5.
By acquiring T3 Pharma, a leader in bacterial cancer treatment, Boehringer Ingelheim broadens its offering in immunooncology.
1.
Pharmacological Frontier of Precision Oncology, Immunotherapies, and the Evolving Art of Treatment
2.
Exploring the Unseen: Carcinoid Syndrome and its Impact on Quality of Life
3.
Revolutionizing Cancer Treatment: The Promise of Bevacizumab Injections
4.
All You Need To Know About Cancer Antigen 27-29: Causes, Symptoms & Treatment
5.
Multiple Primary Lung Cancer: Multidisciplinary Advances in Diagnosis and Care
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Future of Hematology
2.
Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion
3.
The Role of Platelets in Normal Blood Clotting
4.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
5.
Understanding Common Causes of Abnormal Blood Counts
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation